Ratio Therapeutics Funding: $90M Raised, Series B (2024)
Ratio Therapeutics is a Biotech company. It has raised $90M in total funding. Latest round: Series B. Backed by Schusterman, Duquesne, PagsGroup.
Ratio Therapeutics funding overview
Ratio Therapeutics is a Biotech company. Ratio Therapeutics has raised $90M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in November 2024. The round record for Ratio Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Schusterman, Duquesne, PagsGroup, Bristol Myers Squibb, Center for Technology Licensing at Cornell University. 5 distinct backers are named across the disclosed rounds.
Ratio Therapeutics at a glance
Total raised
$90M
Latest round
Series B
Latest round date
November 2024
Industry
Biotech
Notable investors
Schusterman, Duquesne, PagsGroup, Bristol Myers Squibb, Center for Technology Licensing at Cornell University
Frequently asked about Ratio Therapeutics funding
How much has Ratio Therapeutics raised?
Ratio Therapeutics has raised $90M in total disclosed funding across the rounds on record.
Who has invested in Ratio Therapeutics?
Schusterman, Duquesne, PagsGroup, Bristol Myers Squibb, Center for Technology Licensing at Cornell University are named among the investors backing Ratio Therapeutics.
What was the latest Ratio Therapeutics funding round?
The most recent disclosed round is a Series B, announced in November 2024.
Where is Ratio Therapeutics based?
No headquarters location is disclosed for Ratio Therapeutics.
What sector does Ratio Therapeutics operate in?
Ratio Therapeutics is tracked under Biotech, with $90M in disclosed funding.
When did Ratio Therapeutics last raise?
The last disclosed Ratio Therapeutics round closed in November 2024 at Series B.
Every Ratio Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies at a similar stage.
